Taebong Pyeongdong Plant Earns GMP Certification for Tampon Category

Dong-A Pharmaceutical announced on September 16 that Taebong Pyeongdong Plant, the manufacturing facility for its feminine hygiene brand Tempo tampons, has received Good Manufacturing Practice (GMP) certification for quasi-drugs.


Tempo, the feminine hygiene product brand of Dong-A Pharmaceutical. Dong-A Pharmaceutical

Tempo, the feminine hygiene product brand of Dong-A Pharmaceutical. Dong-A Pharmaceutical

View original image

Taebong Pyeongdong Plant recently obtained GMP certification for the 'tampon' category from the Gwangju Regional Food and Drug Administration. As a facility that has been responsible for producing Tempo tampons, the plant manages tampon production by leveraging its manufacturing experience and quality control capabilities.


The quasi-drug GMP is a standard designed to ensure consistent management of overall product quality, including manufacturing facilities, hygiene control, raw material management, production and process management, and quality assurance. Taebong Pyeongdong Plant oversees the entire production process, from raw material receipt to manufacturing, inspection, packaging, storage, and shipping.


This certification was the result of reorganizing its voluntarily implemented tampon manufacturing and quality control systems to comply with GMP standards, thereby strengthening the level of management.

The certified tampon products include Tempo Regular, Tempo Super, Tempo Natural Regular, and Tempo Natural Super.



A representative from Dong-A Pharmaceutical stated, "Through this latest GMP certification, we have verified that our manufacturing and quality management system at the facility producing Tempo tampons operates in accordance with GMP standards," adding, "We will continue our efforts to further enhance our quality control measures to provide trustworthy products to consumers."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing